Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | tyrosyl-DNA phosphodiesterase, putative | 0.0065 | 0.1552 | 0.5 |
Trypanosoma cruzi | tyrosyl-DNA Phosphodiesterase (Tdp1), putative | 0.0065 | 0.1552 | 0.5 |
Echinococcus multilocularis | tyrosyl DNA phosphodiesterase 1 | 0.0065 | 0.1552 | 0.1627 |
Echinococcus granulosus | tyrosyl DNA phosphodiesterase 1 | 0.0065 | 0.1552 | 0.1552 |
Trypanosoma brucei | tyrosyl-DNA Phosphodiesterase (Tdp1), putative | 0.0065 | 0.1552 | 0.5 |
Schistosoma mansoni | retinoic acid receptor RXR | 0.0213 | 1 | 1 |
Trypanosoma cruzi | tyrosyl-DNA Phosphodiesterase (Tdp1), putative | 0.0065 | 0.1552 | 0.5 |
Loa Loa (eye worm) | tyrosyl-DNA phosphodiesterase | 0.0065 | 0.1552 | 0.5 |
Echinococcus multilocularis | retinoic acid receptor rxr beta a retinoic acid receptor rxr alpha a retinoic acid receptor rxr alpha | 0.0205 | 0.9542 | 1 |
Leishmania major | tyrosyl-DNA phosphodiesterase 1 | 0.0065 | 0.1552 | 0.5 |
Brugia malayi | Tyrosyl-DNA phosphodiesterase family protein | 0.0065 | 0.1552 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.